Phase 3
Completed N=8
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
Source: ClinicalTrials.gov NCT00149734 ↗Enrolled (actual)
8
Serious AEs
—
Results posted
Aug 2021
Primary outcomePrimary: P50 Sensory Gating — 41.4; 80.2 percentage
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY P50 Sensory Gating |
41.4; 80.2 | — |
| PRIMARY Cognitive Testing |
— | — |
Eligibility Criteria
Inclusion Criteria
- Meets DSM-IV criteria for schizophrenia
- Stable, chronic schizophrenia
- Currently taking atypical medications
- Use of effective form of contraception throughout study
Exclusion Criteria
- History of any alcohol or drug abuse within 3 months of study start date
- Any other major neurological disorders
- History of or current head trauma
- Any medical conditions affecting the central nervous system
- Current epilepsy, asthma, migraine headache, previous myocardial infarction, stroke, diabetes, hypertension, narrow angle glaucoma, or neuromuscular illnesses
- Pregnant
Data sourced from ClinicalTrials.gov (NCT00149734). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.